Docoh
Loading...

VRNA Verona Pharma

Filed: 12 Nov 20, 6:40am


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
______________________________________________________________________
 
FORM 6-K
 
______________________________________________________________________
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2020
 
______________________________________________________________________

Commission File Number: 001-38067
 
______________________________________________________________________

Verona Pharma plc
(Translation of registrant's name into English)
 
 ______________________________________________________________________

3 More London Riverside
London SE1 2RE UK
+44 203 283 4200
(Address of principal executive office)
 
  ______________________________________________________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K




On November 11, 2020, Verona Pharma plc posted or made available to its shareholders on its website certain material related to the general meeting of shareholders to be held on December 18, 2020 (the “Shareholder Materials”).

The Shareholder Materials are furnished herewith as Exhibits 1 through 3 to this Report on Form 6-K.
 

EXHIBIT INDEX


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
VERONA PHARMA PLC
Date: November 12, 2020 By: /s/ David Zaccardelli
  Name: David Zaccardelli, Pharm. D.
  Title: President and Chief Executive Officer